Page 3
-
Device firms back latest MDUFA deal, while patients want more postmarket safety
The latest agreement includes higher fees for overseas firms, hiring transparency requirements and greater use of real-world evidence.
-
IRhythm grows heart monitoring leadership with $288M VitalConnect buy
Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.
-
Q&A
When does it make sense to build software instead of buy? One health system’s answer.
NYU Langone Health and Dana-Farber Cancer Institute built an oncology decision support tool to guide clinicians through treatment. Now, the institutions are commercializing the product so other health systems can use it too.
-
FDA sets advisory panel for Galleri multicancer screening test
Outside experts will convene in September to review Grail’s premarket approval application for the MCED blood test. Experts selected for the committee will be key to watch, an analyst said.
-
Medtronic gets CE mark for ablation to treat ventricular tachycardia
Older ablation approaches for ventricular tachycardia have been suboptimal, Medtronic said. The company plans to bring a more effective treatment for the life-threatening heart condition.
-
Philips forms 6 patient monitoring partnerships
By employing wearable devices to support patient monitoring between the hospital and home, Philips hopes to improve care continuity.
-
Q&A
Medtronic on the future of AI-assisted surgery
Medtronic’s George Murgatroyd says an advanced computing platform that works with the company’s Hugo robot will power AI algorithms that can assist surgeons as they operate.
-
Zimmer Biomet sales force revamp going better than expected, CEO says
The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.
To find more content, use the "Topics" in the menu above.